Women with Huntington’s disease are more likely to experience irritability and to be unemployed or working part-time than men with the neurodegenerative condition, according to a small, single-center study in Austria. Men and women with Huntington’s showed similar genetic burden, age at disease onset, and motor symptom severity, suggesting that sex-related differences in Huntington’s may […]
The post Genetic burden similar, but HD’s social impact hits women harder appeared first on Huntington's Disease News.
Several years ago, at a family reunion, I discovered something remarkable about my wife Jill’s approach to difficult conversations that has stayed with me ever since. This discovery has become even more important as Jill deals with the challenges of being gene-positive with Huntington’s disease (HD). At the reunion, Jill sat with her extended family, engaging […]
The post The power of constructive dialogue in life with Huntington’s appeared first on Huntington's Disease News.
I can feel it before anyone says a word. It’s in the pause that comes after I mention Huntington’s disease. It’s in the quick scan of my body, my hands, my face, the way I shift my weight like they’re looking for proof. It’s in the softened voice, the head tilt, the “Oh wow. You’re […]
The post I insist on being seen as I am, not as someone else’s story appeared first on Huntington's Disease News.
The U.S. Food and Drug Administration (FDA) has asked uniQure to conduct an additional clinical trial before submitting an application seeking approval of its experimental gene therapy, AMT-130, for Huntington’s disease. That’s according to a press release from uniQure announcing the final minutes of a Type A meeting held with the agency on Jan. 30 […]
The post FDA requests additional clinical trial of Huntington’s gene therapy AMT-130 appeared first on Huntington's Disease News.
If there’s one thing Huntington’s disease (HD) has taught me and my wife, Jill, who is gene-positive with the illness, it’s that rest isn’t a reward; it’s a necessity. Between the disease’s relentless advancement, the daily logistics of symptom management, and the invisible emotional toll, we sometimes forget that our batteries need charging, too. HD […]
The post A log cabin miles from anywhere was just what the doctor ordered appeared first on Huntington's Disease News.
The thing about being present in public is that people think it’s just a mindset. Like you decide to show up, take a deep breath, smile, and you’re there — grounded, confident, fine. But when you live with Huntington’s disease, being present in public can feel like a full-time job you don’t get paid for. […]
The post The invisible battle of staying present with Huntington’s disease appeared first on Huntington's Disease News.
Combining pridopidine and FA10, two investigational compounds for Huntington’s disease that target different proteins in the brain, was found to protect against nerve cell death better than either treatment alone. That’s according to a new study that used a cellular model of the genetic disorder to assess the potential benefits of using these two different […]
The post Combining 2 drugs could slow nerve cell death in Huntington’s: Study appeared first on Huntington's Disease News.
For years before her 2018 diagnosis with Huntington’s disease (HD), my wife, Jill, worked with children at a school. One of her fondest memories is of seeing shy children find their voice thanks to a teacher’s encouragement. “All they needed,” she said, “was for someone to say to them, ‘Your voice matters.’” The HD community […]
The post Your voice matters to the Huntington’s disease community appeared first on Huntington's Disease News.
Some days, my brain feels like it’s buffering. Not in a dramatic, emergency kind of way. It’s more like I’m standing in my kitchen with a cup in my hand, trying to remember why I walked in there in the first place. I can see what needs to happen next, but I can’t always access […]
The post Tiny systems that keep my life moving with Huntington’s disease appeared first on Huntington's Disease News.
U.K. biotech company Harness Therapeutics has selected HRN001 as its lead experimental treatment candidate for Huntington’s disease. “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community,” Jan Thirkettle, PhD, CEO of Harness, said in a company press release. The therapy works by increasing levels of […]
The post UK company selects HRN001 as its lead Huntington’s therapy candidate appeared first on Huntington's Disease News.
When a building catches fire, most of us instinctively move back. We watch from the sidewalk, hoping the flames die down, grateful for any distance between us and the danger. Firefighters are different. They hear the alarm, size up the risk, and move toward the heat, knowing there are no guarantees, only training, courage, and […]
The post Giving thanks for the brave volunteers who participate in HD clinical trials appeared first on Huntington's Disease News.
Dating with Huntington’s disease (HD) has taught me how quickly people confuse honesty with a warning label. I used to believe that telling the truth early on in the process was the kindest thing I could do. I still believe in honesty, but I’ve learned that it doesn’t protect me from being misunderstood. Sometimes it […]
The post The challenges of navigating dating while living with Huntington’s disease appeared first on Huntington's Disease News.
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has given Sarepta Therapeutics the go-ahead to start a first-in-human Phase 1 clinical trial of its investigational therapy SRP-1005 for Huntington’s disease. Sarepta plans to start the trial, dubbed Study SRP-1005-101 or INSIGHTT, between April and June, according to a company press release. It will evaluate the safety […]
The post New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005 appeared first on Huntington's Disease News.
Every year, I write my wife, Jill, something romantic in this column, such as a Valentine’s Day play. This year, she looked at me, half amused and half worried, and said, “Carlos, I don’t know how you haven’t run out of puns by now.” The real issue was unspoken: How many more years do we […]
The post Nothing compares to a punny Valentine’s Day play appeared first on Huntington's Disease News.
February has a quiet way of exposing what the holidays can hide. In December, people check in. They send the “thinking of you” texts. They ask how you’re holding up. Even the people who don’t know what to say still make an effort to say something, because the season almost gives them permission to be […]
The post It’s OK to reach out for help during the February slump appeared first on Huntington's Disease News.
Nine months of treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 appears to have slowed disease progression relative to its natural course in people with early-stage Huntington’s disease. That’s according to new interim data from a substudy, or Part C (ACTRN12624000602527), of an Australia-based Phase 1 clinical trial (ACTRN12623001161617) involving adults with the progressive disorder. Further, these results […]
The post Huntington’s treatment safely slows disease over 9 months in early trial appeared first on Huntington's Disease News.
Comedian and actor Will Forte is teaming up with Teva Pharmaceuticals to raise awareness about Huntington’s disease (HD). Forte has signed on as an ambassador for Teva’s Honestly HD campaign, sharing his family’s story with Huntington’s in hopes of offering resources and connection to people in the HD community. “Any meaningful step forward in Huntington’s disease has to […]
The post Actor Will Forte shares family story in Teva awareness campaign appeared first on Huntington's Disease News.
Ingrezza (valbenazine) engages with its VMAT2 target more strongly than extended-release Austedo XR (deutetrabenazine), which may translate into better control of chorea by more effectively reducing excess dopamine, the cause of these uncontrolled movements in Huntington’s disease and tardive dyskinesia, according to a study. Both medications are approved for the two diseases. In a head-to-head […]
The post Ingrezza engages with therapeutic target more strongly than Austedo appeared first on Huntington's Disease News.
Loqus23 Therapeutics said it is advancing LQT-23 for development as a first-in-class oral treatment for Huntington’s disease. The company said LQT-23 has the potential to slow or halt the onset and progression of the disease, and it plans to submit applications seeking permission to bring the experimental therapy into clinical testing this year. “The nomination […]
The post Oral Huntington’s treatment aims to slow disease progression appeared first on Huntington's Disease News.
The team at Huntington’s Disease News covered the latest community developments and updates in research related to Huntington’s disease throughout 2025. We’ve compiled a list of the top five most-read articles we published in 2025. We look forward to continuing to serve the Huntington’s community in the years to come as a source for news and information. […]
The post Top 5 Huntington’s disease news stories of 2025 appeared first on Huntington's Disease News.
